Abstract
Purpose: Osteoarthritis is a debilitating disease characterized by gradual deterioration of the structural components of the joint, including cartilage and bone. Currently no disease modifying osteoarthritis drugs are available to halt or change the course of the disease. APPA is being developed for the treatment of osteoarthritis (OA) and other pain-related and inflammatory conditions. It consists of a combination of apocynin and its isomer paeonol. The objective of the study was to investigate the effects of APPA on structural tissue turnover assessed by quantifying biochemical markers of extra-cellular matrix remodeling in an ex vivo model of human OA cartilage and an in vitro model of human osteoclast differentiation and resorption.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
